FDA: Page
-
Novartis slapped with $12.6M fine for fuzzy Medicare pricing math
It amounts to the largest such fine ever paid to the federal government.
By Nicole Gray • March 17, 2015 -
Why China's drug approval backlog spiked last year
In 2014, the number of drugs waiting for approval in China increased by a third.
By Nicole Gray • March 17, 2015 -
US District Judge says FDA can revoke Ranbaxy drug approvals
The FDA can revoke approval of generic Nexium and Valcyte, but the judge wants to know why it took so long.
By Nicole Gray • March 16, 2015 -
Merck's anesthesia reversal drug faces 3rd likely FDA rejection
FDA inspectors have said that more sugammadex-injection clinical trial site inspections are needed.
By Nicole Gray • March 16, 2015 -
Public Citizen to FDA: Don't let sales reps distribute data downplaying drug risks
At issue is an FDA proposal to allow reps to circulate peer-reviewed content with new risk data.
By Nicole Gray • March 12, 2015 -
Deep Dive
Will Pradaxa reversibility be the final death knell for warfarin?
Since 2010, warfarin has lost 25% market share to the new class of oral anticoagulants. So what's next for warfarin? And what's next for Pradaxa?
By Nicole Gray • March 12, 2015 -
J&J to pay $25 million to settle children's Tylenol, Motrin contamination case
At the center of this controversy is J&J consumer health arm McNeil's failure to properly investigate complaints of adulterated bottles of children's OTC medications.
By Nicole Gray • March 12, 2015 -
India denies patent protection to Bayer, BI blockbusters
Citing failure to meet inventiveness requirements, India has stuck down patents for Bayer's Nexavar and Boehringer Ingelheim's Spiriva.
By Nicole Gray • March 12, 2015 -
More black box grief for Pfizer's Chantix as FDA adds alcohol, seizure warnings
The smoking cessation drug decreases alcohol tolerance and increases seizure risk, according to a new FDA safety communication.
By Nicole Gray • March 11, 2015 -
United Therapeutics nabs priority review voucher, approval for rare pediatric cancer drug
The voucher could be worth tens of millions of dollars.
By Nicole Gray • March 11, 2015 -
What's next for Kythera after unanimous FDA rec for its double-chin injection?
ATX-101 is a formulation of synthetically derived deoxycholic acid, which targets and destroys localized fat under the chin.
By Nicole Gray • March 10, 2015 -
Astellas nabs FDA approval for new antifungal
Cresemba (isavuconazonium sulfate) is the sixth approved drug under the FDA's Qualified Infectious Disease Product (QIDP) designation.
By Nicole Gray • March 9, 2015 -
Dawn of a new era: FDA approves first-ever biosimilar, Novartis/Sandoz's Zarxio
Biosimilars have finally come to America.
By Nicole Gray • March 6, 2015 -
Flu vax committee picks next year's virus strains after 2014 debacle
The committee is trying to improve upon this year's vaccine's dismal 23% effectiveness rate.
By Nicole Gray • March 6, 2015 -
FDA New Drugs chief: Orexigen's sunny Contrave heart data 'likely false'
And fines, penalties, and even market withdrawal of the drug could be on the horizon if Orexigen doesn't find a way to fix this.
By Sy Mukherjee • March 6, 2015 -
FDA to pharma: Watch out for unapproved Facebook claims
In the last six months, the FDA has issued six warnings to six different companies for posting unapproved claims on their Facebook pages.
By Nicole Gray • March 6, 2015 -
Deep Dive
21st Century Cures: Making Breakthrough Therapy designations more effective
Rep. Fred Upton (R-MI), chair of the House Energy and Commerce Committee, is aggressively pushing an agenda focused on regulatory reform—and it’s starting to happen.
By Nicole Gray • March 5, 2015 -
BMS' Opdivo wins lung cancer indication more than 3 months before PDUFA date
The expanded indication comes mere days after the FDA granted the drug priority review status for lung cancer.
By Nicole Gray • March 4, 2015 -
BI files its Pradaxa 'antidote' in North America, EU
Boehringher Ingelheim has submitted applications to the FDA, the EMA, and Health Canada for idarucizumab.
By Nicole Gray • March 4, 2015 -
SEC to pharma: Don't get cute with disclosing FDA dealings to investors
"Accuracy of reporting in your dealings with the FDA is critical to getting investors the information they need," SEC enforcement director Andrew Ceresney told pharma companies on Tuesday.
By Sy Mukherjee • March 4, 2015 -
FDA clamps down on testosterone labeling rules
The FDA is requiring that drug makers change labeling to inform users of increased risk of heart attack and stroke.
By Nicole Gray • March 4, 2015 -
Orexigen shoots itself in foot with early disclosure of positive Contrave heart data
Disclosure of interim evidence that Contrave (naltrexone) may prevent heart attacks (instead of causing them) should be a good thing. But Orexigen broke FDA rules and Data Monitoring Committee protocol.
By Nicole Gray • March 4, 2015 -
Celgene's Abraxane approved in EU for first-line treatement of NSCLC
The drug is now approved in the E.U. for first-line treatment in combination with carboplatin in adults who are not eligible for radiation or surgery.
By Nicole Gray • March 3, 2015 -
Sponsored by
Color Consistency in Pharmaceuticals: Using Spectrophotometry for Blending Powders and Plaques
Sponsored by: We use the word "color consistency" a lot when referring to products that depend on this trait for quality assurance. In the pharmaceutical industry, color consistency means a lot more than the final color outcome of a product. Color consistency in pharmaceutical powders and pl...
March 3, 2015 -
Sanofi's Toujeo nabs EU rec and efficacy shoutout on heels of FDA blessing
The EMA's Committee for Medicinal Products for Human Use (CHMP) is recommending approval of Toujeo, meaning the drug will win marketing authority in major EU markets soon enough.
By Nicole Gray • March 2, 2015